Hydroxyethyl starches in the intensive care unit;Hydroxyéthylamidons en réanimation

Reanimation

Volumn 23, Issue 2, 2014, Pages 159-166

  Schortgen, F ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Acute kidney injury; Colloids; Crystalloids; Hydroxyethyl starches; Intensive care unit

Indexed keywords

HETASTARCH;

CRITICALLY ILL PATIENT; FLUID RESUSCITATION; HUMAN; INTENSIVE CARE UNIT; MOLECULAR WEIGHT; MORTALITY; NEPHROTOXICITY; REVIEW; RISK BENEFIT ANALYSIS;

EID: 84898863677     PISSN: 16240693     EISSN: 19516959     Source Type: Journal    
DOI: 10.1007/s13546-014-0855-3     Document Type: Review

References (77)

1. Bayliss WM (1919) Intravenous injections of gum solution in cholera. Br Med J 2:450
2. Warren J, Stead E, Merrill A, et al (1944) Chemical, clinical, and immunological studies on the products of human plasma fraction. The treatment of shock with concentrated human serum albumin: a preliminary report. J Clin Invest 23:506-9
3. SRLF-SFAR (1997) Remplissage vasculaire au cours des hypovolémies vraies ou relatives. Réanimation-Urgences 6:333-41
4. Legendre C, Thervet E, Page B, et al (1993) Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 342:248-9 (Pubitemid 23214667)
5. Cittanova ML, Leblanc I, Legendre C, et al (1996) Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 348:1620-2 (Pubitemid 27007061)
6. Schortgen F, Lacherade JC, Bruneel F, et al (2001) Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357:911-6 (Pubitemid 32247279)
7. Thompson WL, Fukushima T, Rutherford RB, et al (1970) Intravascular persistence, tissue storage, and excretion of hydroxyethyl starch. Surg Gynecol Obstet 131:965-72
8. Rudowski W, Kostrzewska E (1976) Blood substitutes. Ann R Coll Surg Engl 58:115-25
9. Stander S, Bone HG, Machens HG, et al (2002) Hydroxyethyl starch does not cross the blood-brain or the placental barrier but the perineurium of peripheral nerves in infused animals. Cell Tissue Res 310:279-87 (Pubitemid 35435771)
10. Auwerda JJ, Wilson JH, Sonneveld P (2002) Foamy macrophage syndrome due to hydroxyethyl starch replacement: a severe side effect in plasmapheresis. Ann Intern Med 137:1013-4 (Pubitemid 35440253)
11. Sirtl C, Laubenthal H, Zumtobel V, et al (1999) Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. Br J Anaesth 82:510-5 (Pubitemid 29151229)
12. Christidis C, Mal F, Ramos J, et al (2001) Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 35:726-32 (Pubitemid 34717663)
13. Leuschner J, Opitz J, Winkler A, et al (2003) Tissue storage of 14C-labelled hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 after repeated intravenous administration to rats. Drugs R D 4:331-8
14. Parker NE, Porter JB, Williams HJ, et al (1982) Pruritus after administration of hetastarch. Br Med J (Clin Res Ed) 284:385-6 (Pubitemid 12171698)
15. Bork K (2005) Pruritus precipitated by hydroxyethyl starch: a review. Br J Dermatol 152:3-12
16. Stander S, Richter L, Osada N, et al (2013) Hydroxyethyl starch-induced pruritus: clinical characteristics and influence of dose, molecular weight and substitution. Acta Derm Venereol doi:10.2340/00015555-1639. [Epub ahead of print]
17. Dickenmann M, Oettl T, Mihatsch MJ (2008) Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 51:491-503 (Pubitemid 351273478)
18. Pillebout E, Nochy D, Hill G, et al (2005) Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 5:1120-9 (Pubitemid 40571263)
19. Hagne C, Schwarz A, Gaspert A, et al (2009) HAES in der Sepsis: ein Damoklesschwert? Schweiz Med Forum 9:304-6
20. Druml W, Polzleitner D, Laggner AN, et al (1988) Dextran-40, acute renal failure, and elevated plasma oncotic pressure. N Engl J Med 318:252-4
21. Kief H, Engelbart K, Arnold G, et al (1968) Vacuolar reabsorption of native and digested gelatin (so-called osmotic nephrosis). Virchows Arch B Cell Pathol 1:240-50
22. Bhatt AP, Neppalli VT, Kelley EA, et al (2011) Dextran removal by plasmapheresis in a kidney-pancreas transplant recipient with dextran 40-induced osmotic nephrosis. Am J Kidney Dis 57:621-3
23. Schick MA, Isbary TJ, Schlegel N, et al (2009) The impact of crystalloid and colloid infusion on the kidney in rodent sepsis. Intensive Care Med 36:541-8
24. Economidou D, Kapoukranidou D, Dimitriadis C, et al (2011) Osmotic nephrosis due to the use of anti-adhesive membrane intraperitoneally. Nephro Dial Transplant 26:697-701
25. Economidou D, Stavrinou E, Giamalis P, et al (2011) Acute kidney injury due to osmotic nephrosis following intraoperative placement of an intraperitoneal antiadhesive barrier. Am J Kidney Dis 57:304-7
26. Schortgen F, Girou E, Deye N, et al (2008) The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 34:2157-68
27. Schortgen F, Brochard L (2009) Colloid-induced kidney injury: experimental evidence may help to understand mechanisms. Crit Care 13:130
28. Bayer O, Reinhart K, Kohl M, et al (2012) Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance and patient outcomes in patients with severe sepsis: a prospective sequential analysis. Crit Care Med 40:2543-51
29. Reinhart K, Perner A, Sprung CL, et al (2012) Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med 38:368-83
30. Brunkhorst FM, Engel C, Bloos F, et al (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125-39
31. Perner A, Haase N, Guttormsen AB, et al (2012) Hydroxyethyl starch 130/0.4 versus Ringer's acetate in severe sepsis. N Engl J Med 367:124-34
32. Myburgh JA, Finfer S, Bellomo R, et al (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367:1901-11
33. Brandt S, Regueira T, Bracht H, et al (2009) Effect of fluid resuscitation on mortality and organ function in experimental sepsis models. Crit Care 13:R186
34. De Labarthe A, Jacobs F, Blot F, et al (2001) Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. Am J Med 111:417-8 (Pubitemid 32913681)
35. Kumar AB, Suneja M (2012) Hetastarch-induced osmotic nephrosis. Anesthesiology 117:647
36. Ebcioglu Z, Cohen DJ, Crew RJ, et al (2006) Osmotic nephrosis in a renal transplant recipient. Kidney Int 70:1873-6 (Pubitemid 44684821)
37. Jungheinrich C, Scharpf R, Wargenau M, et al (2002) The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 ml) in mild-to-severe renal impairment. Anesth Analg 95:544-51 (Pubitemid 35006837)
38. Westphal M, James MF, Kozek-Langenecker S, et al (2009) Hydroxyethyl starches: different products - different effects. Anesthesiology 111:187-202
39. Eisenbach C, Schonfeld AH, Vogt N, et al (2007) Pharmacodynamics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: influence of molecular weightand degree of substitution. Intensive Care Med 33:1637-44 (Pubitemid 47312475)
40. Huter L, Simon TP, Weinmann L, et al (2009) Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model. Crit Care 13:R23
41. Haynes GR (2006) Fluid management in cardiac surgery: is one hydroxyethyl starch solution safer than another? J Cardiothorac Vasc Anesth 20:916-7
42. Brochard L, Schortgen F, Brun-Buisson C, et al (2008) Pour un moratoire sur l'utilisation des hydroxyéthylamidons. Réanimation 17:588-91
43. Zarychanski R, Turgeon AF, Fergusson DA, et al (2009) Renal outcomes following hydroxyethl starch resuscitation: a meta-analysis of randomized trials. Open Med 3:e196-e209
44. Guidet B, Martinet O, Boulain T, et al (2012) Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 versus 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 16:R94
45. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/NewDrugApplicationsNDAs/UCM220167.pdf?bcsi-scan- 628cd39dca2568d2=T6nsJ1fMDaQ28ANjTXH30R75RAUCAAAAb36aCQ==&bcsi-scan- filename=UCM220167.pdf, accédé le 21/10/2013
46. http://www.fda.gov/biologicsbloodvaccines/safetyavailability/ucm358271. htm, accédé le 19/10/2013
47. Hartog CS, Reinhart K (2012) CRYSTMAS study adds to concerns about renal safety and increased mortality in sepsis patients. Crit Care 16:454
48. Haase N, Wetterslev J, Winkel P, et al (2013) Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post-hoc analyses of a randomized clinical trial. Intensive Care Med 39:2126-34
49. Meybohm P, Van Aken H, De Gasperi A, et al (2013) Re-evaluating currently available data and suggestions for planning randomised controlled studies regarding the use of hydroxyethyl-starch in critically ill patients: a multidisciplinary statement. Crit Care 17:R166
50. Patel A, Waheed U, Brett SJ (2013) Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med 39:811-22
51. Mutter TC, Ruth CA, Dart AB (2013) Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 7:CD007594
52. Haase N, Perner A, Hennings LI, et al (2013) Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 346:f839
53. Gattas DJ, Dan A, Myburgh J, et al (2013) Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 39:558-68
54. Zarychanski R, Abou-Setta AM, Turgeon AF, et al (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309:678-88
55. Perel P, Roberts I, Ker K (2013) Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2:CD000567
56. Annane D, Siami S, Jaber S, et al (2013) Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 310:1809-17
57. http://clinicaltrials.gov/archive/NCT00318942/2007-05-09/changes, accédé le 21/10/2013
58. The SAFE Study Investigators (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350:2247-56
59. Nisula S, Kaukonen KM, Vaara ST, et al (2013) Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. Intensive Care Med 39:420-8
60. Rioux JP, Lessard M, De Bortoli B, et al (2009) Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery. Crit Care Med 37:1293-8
61. Winkelmayer WC, Glynn RJ, Levin R, et al (2003) Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney Int 64:1046-9 (Pubitemid 37013841)
62. Muller RG, Haase N, Wetterslev J, et al (2013) Effects of hydroxyethyl starch in subgroups of patients with severe sepsis: exploratory post-hoc analyses of a randomised trial. Intensive Care Med 39:1963-71
63. Bechir M, Puhan MA, Neff SB, et al (2010) Early fluid resuscitation with hyperoncotic hydroxyethyl starch 200/0.5 (10%) in severe burn injury. Crit Care 14:R123
64. Hartog CS, Kohl M, Reinhart K (2011) A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg 112:635-45
65. Wise J (2013) Boldt: the great pretender. BMJ 346:f1738
66. Antonelli M, Sandroni C (2013) Hydroxyethyl starch for intravenous volume replacement: more harm than benefit. JAMA 309:723-4
67. Finfer S, Liu B, Taylor C, et al (2010) Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care 14:R185
68. Hartog CS, Skupin H, Natanson C, et al (2012) Systematic analysis of hydroxyethyl starch (HES) reviews: proliferation of low-quality reviews overwhelms the results of well-performed meta-analyses. Intensive Care Med 38:1258-71
69. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ referrals/Hydroxyethyl-starch-containing-solutions/human-referral-prac-000012. jsp&mid=WC0b01ac05805c516f accédé le 21/10/2013
70. http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/ Solutions-for-infusion-containing-hydroxyethyl-starch/Recommendation-provided- by-Pharmacovigilance-Risk-Assessment-Committee/WC500144448.pdf, accédé le 21/10/2013
71. Vincent JL, Kellum JA, Shaw A, et al (2013) Should hydroxyethyl starch solutions be totally banned? Crit Care 17:193
72. Chappell D, Jacob M (2013) Hydroxyethyl starch - the importance of being earnest. Scand J Trauma Resusc Emerg Med 21:61
73. Godet G, Girard C, Guidet B, et al (2013) Hydroxyethylstarches and renal failure: to keep the reason is a necessity. Ann Fr Anesth Reanim 32:535-8
74. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON286974, accédé le 21/10/2013
75. Bion J, Bellomo R, Myburgh J, et al (2013) Hydroxyethyl starch: putting patient safety first. Intensive Care Med [Epub ahead of print]
76. http://ansm.sante.fr/S-informer/Actualite/Medicaments-contenant-le- facteur-VIII-octocog-alpha-medicaments-contenant-de-l-hydroxyethylamidon- medicaments-contenant-du-valproate-les-contraceptifs-hormonaux-combines- cabazitaxel-Jevatana-Retour-d-information-sur-le-PRAC, accédé le 19/10/2013
77. http://www.bbc.co.uk/programmes/b038hfr4 accédé le 19/10/2013